Showing 1 - 10 of 43
Most pharmacoeconomic studies of mycophenolate mofetil have focused on its use as part of maintenance immunosuppression for renal transplantation, involving short-term (3-12 months) time frames. In general, mycophenolate mofetil reduced the treatment costs for rejection episodes and graft...
Persistent link: https://www.econbiz.de/10005404609
Insulin lispro is a recombinant insulin analog with transposed amino acids (proline and lysine) at positions 28 and 29 near the C-terminus of the B-chain. The most prominent practical advantage of insulin lispro over human soluble insulin lies in its very rapid onset of action. This property...
Persistent link: https://www.econbiz.de/10005404672
Postmenopausal osteoporosis is characterized by an increased rate of bone turnover accompanied by a reduction in bone mineral density (BMD) that results in an increased risk of fracture, especially of the vertebrae, hip, or wrist. Alendronate (Fosamax(R), Fosamax Once-Weekly(R)), an oral...
Persistent link: https://www.econbiz.de/10005404679
Paclitaxel belongs to the group of antitumor agents called the taxanes. Its efficacy in advanced ovarian cancer has been established in large, randomized phase III clinical trials. When used in combination with cisplatin for first-line treatment of advanced ovarian cancer, it is superior to...
Persistent link: https://www.econbiz.de/10005404683
Glipizide is a second generation sulphonylurea agent that is available in a Gastrointestinal Therapeutic System (GITS) extended-release formulation. Glipizide GITS provides more stable plasma drug concentrations than the immediate-release formulation and the once-daily regimen may optimise...
Persistent link: https://www.econbiz.de/10005404789
The addition of candesartan cilexetil (Atacand(R), Amias(R), Blopress(R), Kenzen(R), Ratacand(R)) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany and the UK, according to a detailed economic analysis...
Persistent link: https://www.econbiz.de/10005404816
Most pharmacoeconomic studies of mycophenolate mofetil have focused on its use as part of maintenance immunosuppression for renal transplantation, involving short-term (3 to 12 months) time frames. In general, mycophenolate mofetil reduced the treatment costs for rejection episodes and graft...
Persistent link: https://www.econbiz.de/10005404894
Eptifibatide (Integrilin(R)) is a selective inhibitor of platelet glycoprotein (GP) IIb/IIIa receptors used as adjunctive therapy for patients undergoing percutaneous coronary intervention (PCI) and for patients with acute coronary syndromes (ACS), particularly those requiring PCI. Most economic...
Persistent link: https://www.econbiz.de/10005404996
Escitalopram (Cipralex(R)), a new highly selective serotonin reuptake inhibitor (SSRI), is the active S-enantiomer of RS-citalopram. It is effective in the treatment of patients with major depressive disorder (MDD) and may have a faster onset of therapeutic effect than citalopram. It has also...
Persistent link: https://www.econbiz.de/10005405009
Repaglinide (Prandin(R), NovoNorm(R), GlucoNorm(R)), an oral insulin secretagogue, was the first meglitinide analogue to become available for use in patients with type 2 diabetes mellitus. The drug lowers postprandial glucose excursions by targeting early-phase insulin release, an effect thought...
Persistent link: https://www.econbiz.de/10004990323